Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Ocular Therapeutix (NASDAQ: OCUL) will host a webcast on Tuesday, February 17, 2026 at 8:00 AM ET to review topline results from the SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration.

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) will host a webcast on Tuesday, February 17, 2026 at 8:00 AM ET to review topline results from the SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration.

Detailed SOL-1 data will be presented at the 49th Macula Society Annual Meeting from February 25–28, 2026. The live webcast and archived replay (available for at least 30 days) can be accessed via the company's Investor Relations Events and Presentations page.

Argus Feb 17 session

-21.28% close to close Open Argus

Details

News Market Reaction – OCUL

On Feb 17, the first trading day after this news, OCUL closed 21.28% below the previous close.

Data tracked by StockTitan Argus for the Feb 17 session.

Key Figures

SOL-1 topline date: February 17, 2026 Webcast time: 8:00 AM ET Macula Society meeting: 49th annual +2 more

SOL-1 topline date

February 17, 2026

Topline data for Phase 3 SOL-1 superiority trial in wet AMD

Webcast time

8:00 AM ET

Company webcast reviewing SOL-1 topline results

Macula Society meeting

49th annual

Detailed SOL-1 data presentation venue

Macula meeting dates

February 25–28, 2026

Conference window for detailed SOL-1 data

Webcast replay period

At least 30 days

Archived access to SOL-1 topline webcast

Previous Clinical trial Reports

5 past events · Latest: Dec 08

Same Type 5 events

1. Dec 08

   NDA timing update

   24h Move

   +28.1%

   Planned accelerated NDA submission for AXPAXLI after positive SOL-1 topline data.

2. Nov 24

   Phase 3 enrollment

   24h Move

   -1.1%

   First patient randomized in HELIOS-3 Phase 3 NPDR trial with novel DRSS endpoint.

3. Sep 30

   Investor Day trials

   24h Move

   -6.7%

   Investor Day detailing SOL-1 and SOL-R progress and new HELIOS Phase 3 plans.

4. Apr 18

   Phase 1 topline

   24h Move

   -22.7%

   Positive topline Phase 1 data for AXPAXLI in diabetic retinopathy.

5. Feb 13

   Phase 3 start

   24h Move

   -4.4%

   First subjects screened in Phase 3 pivotal AXPAXLI trial in wet AMD.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 3, superiority clinical trial, wet age-related macular degeneration, wet amd, +1 more

5 terms

phase 3 medical

"topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

superiority clinical trial medical

"SOL-1 Phase 3 superiority clinical trial of AXPAXLI"

A superiority clinical trial tests whether a new treatment is actually better than a comparison — usually an existing therapy or a placebo — by measuring specific health outcomes. Investors care because a result showing clear benefit can increase the chance of regulatory approval, premium pricing and market share, while a failed result raises uncertainty; think of it as a race where the new product must prove it finishes ahead to win commercial advantage.

wet age-related macular degeneration medical

"for the treatment of wet age-related macular degeneration (wet AMD)"

A severe eye condition in which abnormal, fragile blood vessels grow beneath the macula — the small central part of the retina responsible for sharp, detailed vision — and leak fluid or blood, causing rapid loss of central sight. Investors care because the condition drives demand for high-cost therapies, medical devices and ongoing care; successful treatments can create sizable markets, affect healthcare spending and influence regulatory and reimbursement decisions, much like fixing a leaking camera lens restores image quality and value.

wet amd medical

"for the treatment of wet age-related macular degeneration (wet AMD)"

Wet AMD (wet age-related macular degeneration) is an eye disease in older adults where abnormal, leaky blood vessels grow under the retina and cause rapid vision loss in the center of the visual field. It matters to investors because it creates a sustained market for treatments, diagnostics and devices: changes in diagnosis rates, new drugs, or reimbursement rules can quickly affect healthcare revenues and the valuation of companies working on therapies.

webcast technical

"Company will host a webcast to review the topline results"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET

Detailed SOL-1 data to be presented at the 49^th Macula Society Annual Meeting

BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), on Tuesday, February 17, 2026. Detailed data will be presented at the 49^th Macula Society Annual Meeting between February 25 – 28, 2026.

Click here to register for the virtual webcast, which will begin at 8:00 AM ET.

The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Ocular Therapeutix (OCUL) release SOL-1 Phase 3 topline results?

The company will review SOL-1 topline results on February 17, 2026 at 8:00 AM ET. According to the company, a live webcast will cover the topline findings and a replay will be archived for at least 30 days.

Where will Ocular Therapeutix (OCUL) present detailed SOL-1 data in February 2026?

Detailed SOL-1 data will be presented at the 49th Macula Society Annual Meeting from February 25–28, 2026. According to the company, the full dataset will be shared during that meeting for clinical review.

How can investors access the OCUL webcast for SOL-1 topline results on February 17, 2026?

Investors can access the live webcast via the company's Investor Relations Events and Presentations page. According to the company, registration is available and an archived replay will be posted for at least 30 days.

What is AXPAXLI (OTX-TKI) and why is the SOL-1 result important for OCUL investors?

AXPAXLI (OTX-TKI) is the SOL-1 Phase 3 study drug for treating wet AMD; topline results indicate trial direction. According to the company, the webcast will summarize primary outcomes ahead of detailed meeting presentation.

Will the OCUL webcast on February 17, 2026 include detailed clinical data or just topline results?

The webcast will review the SOL-1 topline results on February 17, 2026; detailed data will follow. According to the company, full data are scheduled for presentation at the Macula Society meeting February 25–28, 2026.